ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc. (ZVSA): 3 pipeline candidates · ~2 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.6 months
D/E -1.05 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for ZyVersa Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.3M
Cash
$303K
Quarterly Burn
$799K
Runway
1.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Jun 2025Institutional holders
7
Total value held
$45K
| Holder | Shares | Value |
|---|---|---|
| ubs group ag | 39,280 | $27K |
| geode capital management, llc | 21,706 | $15K |
| tower research capital llc (trc) | 4,525 | $3K |
| citigroup inc | 274 | $186 |
| sbi securities co., ltd. | 151 | $102 |
| bank of america corp /de/ | 132 | $90 |
| concourse financial group securities, inc. | 0 | $0 |
Frequently asked questions
How many drug candidates are in ZyVersa Therapeutics, Inc.'s pipeline?
ZyVersa Therapeutics, Inc. (ZVSA) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ZyVersa Therapeutics, Inc.'s lead drug candidate?
ZyVersa Therapeutics, Inc.'s most advanced tracked candidate is 2hpβcd (Phase 2) for Diabetic Kidney Disease.
What is ZyVersa Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ZyVersa Therapeutics, Inc. has approximately 1.6 months of cash runway.
What is ZyVersa Therapeutics, Inc.'s market capitalization?
ZyVersa Therapeutics, Inc.'s market capitalization is approximately $1.3M.
Who is the CEO of ZyVersa Therapeutics, Inc.?
Mr. Stephen C. Glover is the chief executive officer of ZyVersa Therapeutics, Inc. (ZVSA).
Get the full picture on ZyVersa Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.